Yuqi Wu, Canjun Li, Yin Yang, Tao Zhang, Jianyang Wang, Wanxiangfu Tang, Ningyou Li, Hua Bao, Xin Wang, Nan Bi
{"title":"利用ctDNA机器学习模型预测无法手术的局部NSCLC患者的病情进展","authors":"Yuqi Wu, Canjun Li, Yin Yang, Tao Zhang, Jianyang Wang, Wanxiangfu Tang, Ningyou Li, Hua Bao, Xin Wang, Nan Bi","doi":"10.1002/cam4.70316","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>There is an urgent clinical need to accurately predict the risk for disease progression in post-treatment NSCLC patients, yet current ctDNA mutation profiling approaches are limited by low sensitivity. We represent a non-invasive liquid biopsy assay utilizing cfDNA neomer profiling for predicting disease progression in 44 inoperable localized NSCLC patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 97 plasma samples were collected at various time points during or post-treatments (TP1: 39, TP2: 33, TP3: 25). cfDNA neomer profiling, generated based on target sequencing data, was used to fit survival support vector machine models for each time point. Leave-one-out cross-validation (LOOCV) was performed to evaluate the models' predictive performances.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Our cfDNA neomer profiling assay showed excellent performance in detecting patients with a high risk for disease progression. At TP1, the high-risk patients detected by our model showed an increased risk of 3.62 times (hazard ratio [HR] = 3.62, <i>p</i> = 0.0026) for disease progression, compared to 3.91 times (HR = 3.91, <i>p</i> = 0.0022) and 4.00 times (HR = 4.00, <i>p</i> = 0.019) for TP2 and TP3. These neomer profiling determined HRs were higher than the ctDNA mutation-based results (HR = 2.08, <i>p</i> = 0.074; HR = 1.49, <i>p</i>&amp;#x02009;=&amp;#x02009;0.61) at TP1 and TP3. At TP1, the predictive model reached 40% sensitivity at 92.9% specificity, outperforming the mutation-based method (40% sensitivity at 78.6% specificity), while the combination results reached a higher sensitivity (60%). Finally, the longitudinal analysis showed that the combination of neomer and ctDNA mutation-based results could predict disease progression with an excellent sensitivity of 88.9% at 80% specificity.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In conclusion, we developed a cfDNA neomer profiling assay for predicting disease progression in inoperable NSCLC patients. This assay showed increased predicting power during and post-treatment compared to the ctDNA mutation-based method, thus illustrating a great clinical potential to guide treatment decisions in inoperable NSCLC patients.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>ClinicalTrials.gov: NCT04014465</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 20","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499892/pdf/","citationCount":"0","resultStr":"{\"title\":\"Predicting Disease Progression in Inoperable Localized NSCLC Patients Using ctDNA Machine Learning Model\",\"authors\":\"Yuqi Wu, Canjun Li, Yin Yang, Tao Zhang, Jianyang Wang, Wanxiangfu Tang, Ningyou Li, Hua Bao, Xin Wang, Nan Bi\",\"doi\":\"10.1002/cam4.70316\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>There is an urgent clinical need to accurately predict the risk for disease progression in post-treatment NSCLC patients, yet current ctDNA mutation profiling approaches are limited by low sensitivity. We represent a non-invasive liquid biopsy assay utilizing cfDNA neomer profiling for predicting disease progression in 44 inoperable localized NSCLC patients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A total of 97 plasma samples were collected at various time points during or post-treatments (TP1: 39, TP2: 33, TP3: 25). cfDNA neomer profiling, generated based on target sequencing data, was used to fit survival support vector machine models for each time point. Leave-one-out cross-validation (LOOCV) was performed to evaluate the models' predictive performances.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Our cfDNA neomer profiling assay showed excellent performance in detecting patients with a high risk for disease progression. At TP1, the high-risk patients detected by our model showed an increased risk of 3.62 times (hazard ratio [HR] = 3.62, <i>p</i> = 0.0026) for disease progression, compared to 3.91 times (HR = 3.91, <i>p</i> = 0.0022) and 4.00 times (HR = 4.00, <i>p</i> = 0.019) for TP2 and TP3. These neomer profiling determined HRs were higher than the ctDNA mutation-based results (HR = 2.08, <i>p</i> = 0.074; HR = 1.49, <i>p</i>&amp;#x02009;=&amp;#x02009;0.61) at TP1 and TP3. At TP1, the predictive model reached 40% sensitivity at 92.9% specificity, outperforming the mutation-based method (40% sensitivity at 78.6% specificity), while the combination results reached a higher sensitivity (60%). Finally, the longitudinal analysis showed that the combination of neomer and ctDNA mutation-based results could predict disease progression with an excellent sensitivity of 88.9% at 80% specificity.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>In conclusion, we developed a cfDNA neomer profiling assay for predicting disease progression in inoperable NSCLC patients. This assay showed increased predicting power during and post-treatment compared to the ctDNA mutation-based method, thus illustrating a great clinical potential to guide treatment decisions in inoperable NSCLC patients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>ClinicalTrials.gov: NCT04014465</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"13 20\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499892/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70316\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70316","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Predicting Disease Progression in Inoperable Localized NSCLC Patients Using ctDNA Machine Learning Model
Introduction
There is an urgent clinical need to accurately predict the risk for disease progression in post-treatment NSCLC patients, yet current ctDNA mutation profiling approaches are limited by low sensitivity. We represent a non-invasive liquid biopsy assay utilizing cfDNA neomer profiling for predicting disease progression in 44 inoperable localized NSCLC patients.
Methods
A total of 97 plasma samples were collected at various time points during or post-treatments (TP1: 39, TP2: 33, TP3: 25). cfDNA neomer profiling, generated based on target sequencing data, was used to fit survival support vector machine models for each time point. Leave-one-out cross-validation (LOOCV) was performed to evaluate the models' predictive performances.
Results
Our cfDNA neomer profiling assay showed excellent performance in detecting patients with a high risk for disease progression. At TP1, the high-risk patients detected by our model showed an increased risk of 3.62 times (hazard ratio [HR] = 3.62, p = 0.0026) for disease progression, compared to 3.91 times (HR = 3.91, p = 0.0022) and 4.00 times (HR = 4.00, p = 0.019) for TP2 and TP3. These neomer profiling determined HRs were higher than the ctDNA mutation-based results (HR = 2.08, p = 0.074; HR = 1.49, p&#x02009;=&#x02009;0.61) at TP1 and TP3. At TP1, the predictive model reached 40% sensitivity at 92.9% specificity, outperforming the mutation-based method (40% sensitivity at 78.6% specificity), while the combination results reached a higher sensitivity (60%). Finally, the longitudinal analysis showed that the combination of neomer and ctDNA mutation-based results could predict disease progression with an excellent sensitivity of 88.9% at 80% specificity.
Conclusion
In conclusion, we developed a cfDNA neomer profiling assay for predicting disease progression in inoperable NSCLC patients. This assay showed increased predicting power during and post-treatment compared to the ctDNA mutation-based method, thus illustrating a great clinical potential to guide treatment decisions in inoperable NSCLC patients.
期刊介绍：
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
